eXoZymes Inc.
Last updated September 27, 2026
Organization details
- Legal name
- eXoZymes Inc.
- Former names
- Invizyne Technologies Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Nevada
- Headquarters city
- Monrovia
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- EXOZ
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002010788
- EIN
- 83-4550057
Board of directors
- Since 2024
-
Christopher A. Marlett · DirectorSince 2024
-
Edgardo Javier Rayo · DirectorSince 2025
-
James Joseph Lalonde · DirectorSince 2024
-
James Ulrich Bowie · DirectorSince 2024
-
Lon E. Bell · DirectorSince 2024
-
Mohammad Hayat · Director · President & Chairman of BoardSince 2024
Director election results
Annual meeting of July 25, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
99.5%
-
99.5%
-
99.5%
-
100.0%
-
100.0%
-
100.0%
Board connections
3 of this board's directors also sit on 5 other boards.
- via Anthony Digiandomenico, Christopher A. Marlett and Mohammad Hayat
- via Mohammad Hayat
- via Anthony Digiandomenico
- via Anthony Digiandomenico
- via Anthony Digiandomenico
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $6,405
- 5 purchases by 1 insider
- Sold, last 12 months
- $15,428
- 2 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 26, 2026 | Heltzen Michael Officer (Chief Executive Officer) | Open-market purchase | +4 | $7.58 | $30 |
| Aug 26, 2026 | Heltzen Michael Officer (Chief Executive Officer) | Open-market purchase | +251 | $7.35 | $1,845 |
| Aug 26, 2026 | Heltzen Michael Officer (Chief Executive Officer) | Open-market purchase | +250 | $7.60 | $1,900 |
| Aug 25, 2026 | Heltzen Michael Officer (Chief Executive Officer) | Open-market purchase | +250 | $7.52 | $1,880 |
| Aug 25, 2026 | Heltzen Michael Officer (Chief Executive Officer) | Open-market purchase | +100 | $7.50 | $750 |
| Aug 19, 2026 | Korman Tyler Paz Officer (Chief Scientific Officer) | Option exercise | +32,964 | — | — |
| Aug 19, 2026 | Perriman Damien Alan Officer (Chief Commercial Officer) | Option exercise | +19,612 | — | — |
| Aug 19, 2026 | Heltzen Michael Officer (Chief Executive Officer) | Grant or award | +8,841 | $6.40 | $56,582 |
| Apr 9, 2026 | Korman Tyler Paz Officer (Chief Scientific Officer) | Open-market sale | −750 | $10.53 | $7,898 |
| Apr 8, 2026 | Korman Tyler Paz Officer (Chief Scientific Officer) | Open-market sale | −750 | $10.04 | $7,530 |
| Apr 1, 2026 | Perriman Damien Alan Officer (Chief Commercial Officer) | Grant or award | +62,759 | — | — |
| Apr 1, 2026 | Perriman Damien Alan Officer (Chief Commercial Officer) | Grant or award | +8,887 | $8.44 | $75,006 |
| Apr 1, 2026 | Opgenorth Paul Hideo Officer (Vice President, Development) | Grant or award | +3,999 | $8.44 | $33,752 |
| Apr 1, 2026 | Nawaz Fouad Officer (Vice President- Finance) | Grant or award | +5,999 | $8.44 | $50,632 |
| Apr 1, 2026 | Korman Tyler Paz Officer (Chief Scientific Officer) | Grant or award | +5,332 | $8.44 | $45,002 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.